Mercury Laboratories Ltd (BSE: 538964) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹90 Cr, it ranks #3,333 by market cap among the 6,197 Indian listed companies on FinBizNet, and #70 of 86 in Medicinal Chemicals and Botanical Products. At ₹777.70 (as of 16 Nov 2026), the share price is 16.2% below its 52-week high of ₹928.50 and 25.3% above its 52-week low of ₹620.55. The share price is down 8.3% over one year and up 2.7% over three months.
| Current Price | ₹777.70 |
|---|---|
| Market Cap | ₹90 Cr |
| BSE Code | 538964 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.6 |
| Return on Equity | 8.66% |
| Return on Assets | 4.90% |
| 52-Week Range | ₹620.55 – ₹928.50 |
| 1-Year Price Change | -8.3% |
| 3-Month Price Change | +2.7% |
| Beta (1Y) | 0.52 |
| Dividend Yield | 0.47% |
| Headquarters | Vadodara, Gujarat |
| Website | www.mercurylabs.com |
Delivery averaged 92.5% of traded volume across 13 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron and vitamins, pain management, preterm labor management, antiemetic, PPI; vitamin K1, zinc supplement, antiallergic, vitamin D3, digestive enzyme, promolact, antipyretic, and
1. Pharmaceuticals Products-This segment develops, manufactures, markets, distributes, and sells pharmaceuticals, medicinal drugs, and formulations for mother and child healthcare.
1. Pharmaceuticals Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Mercury Laboratories Ltd | ₹90 Cr | 18.6 | 8.66% | — | -8.3% |
Listed by market capitalisation. Ratios are shown for context only.
Mercury Laboratories Ltd is trading at ₹777.70, with a market capitalisation of ₹90 Cr.
Mercury Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Mercury Laboratories Ltd has a P/E of 18.6 and a return on equity of 8.66%.
Mercury Laboratories Ltd is listed on the BSE under the scrip code 538964.
Mercury Laboratories Ltd's share price is down 8.3% over one year and up 2.7% over three months. Its 52-week range is ₹620.55 to ₹928.50.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.